Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide.

Skubitz, Keith M; Lindgren, Bruce R; Domingo-Musibay, Evidio; Cheng, Edward Y

Skubitz, Keith M; Lindgren, Bruce R; Domingo-Musibay, Evidio; Cheng, Edward Y.

Afiliación

Skubitz KM; Medicine, University of Minnesota, Minneapolis, USA.
Lindgren BR; Masonic Cancer Center, University of Minnesota, Minneapolis, USA.
Domingo-Musibay E; Masonic Cancer Center, University of Minnesota, Minneapolis, USA.
Cheng EY; Medicine, University of Minnesota, Minneapolis, USA.

Cureus ; 14(4): e24498, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35651410

Palabras clave

doxorubicin; drug-related side effect; hand-foot syndrome; liposome; monocyte; pegylated-liposomal doxorubicin; pharmacokinetics; sarcoma; toxicity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cureus Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google